S100A7 and Alzheimer disease: This in vitro evidence strongly suggests that the elevation of S100A7 expression in the brain of patients with AD might reflect a novel protective anti-amyloidogenic compensatory mechanism in response to the rampant AD brain amyloidogenesis.